\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe European Commission has set-up a NEB-lab where the New European Bauhaus is implemented in concrete and tangible projects and it also supports the community. One of their first actions is to analyse how the regulatory framework on European, national, regional or local level can support the development of New European Bauhaus projects and which barriers currently exist. To this purpose they have set-up an online survey which architects, engineers, designers, spatial planners, companies and citizens are invited to fill in.
We would also like to draw your attention to the NEB festival which will take place from the 9th till the 12th of June in Brussels. if you want to get involved you can still apply on the website and of course you are more than welcome to join in with the festivities.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
On 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products. This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
